NCT04611724招募中2 期
A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Objective response rate
研究概览
简要总结
This study aims to assess objective response rate of modified FOLFIRINOX in advanced urachaus cancer.
Patients with locally advanced, recurrent, or metastatic urachal carcinoma of bladder, urachal will be enrolled this study.
Modified version of FOLFIRINOX(Oxaliplatin 85 mg/m 2, Leucovorin 400mg/m2 , irinotecan 150mg/m2 and 5-FU 2400mg/m2) with prophylactic pegateograstim will be continued till progression, unacceptable toxicity, or till 12 cycles (24 weeks). Study drugs can be administered after 12 cycles to the subjects with benefit from study medication.
Response evaluation will be done every 6 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed adenocarcinoma of bladder/urachal remnant that is clinically consistent with urachal cancer.
- •Origin in the anterior wall or dome of the bladder Predominant invasion of muscularis or deeper tissues No obvious origin from the overlying urothelium (relative normal-looking urothelial mucosa) No primary adenocarcinoma elsewhere
- •Patients with locally advanced, recurrent, or metastatic disease not amenable to surgery, radiotherapy, or combined modality therapy with curative intent
- •No prior systemic therapy for advanced urachal cancer. For recurrent disease, previous 5-FU, oxaliplatin, or irinotecan chemotherapy as neoadjuvant and/or adjuvant aim is allowed if it ended more than 6 months before enrollment.
- •Measurable disease according to RECIST v1.1 criteria
- •ECOG performance status 0 or 1
- •Age 19 years or older
- •Adequate cardiac function
- •Adequate bone marrow, hepatic, and renal function Hematology
- •Life expectancy more than 3 months
- •Signed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment
- •Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
排除标准
- •Age > 65
- •Previous radiotherapy to the only measurable lesion: but previous radiotherapy will be permitted unless the lesion is the only measurable lesion
- •Uncontrolled CNS metastasis (brain and/or leptomeningeal metastasis)
- •Grade 2 or more peripheral neuropathy
- •Diagnosis of any serious secondary malignancy within the last 2 years, except for adequately treated basal cell or squamous cell carcinoma of skin, or in situ carcinoma of cervix uteri or prostate cancer and curatively treated thyroid cancer of any stage.
- •Pregnancy or breast feeding, or intention of becoming pregnant during study treatment or within 6 months after final dose
- •Other severe acute or chronic medical or psychiatric condition
- •Chronic diarrhea
- •Clinically significant cardiac disease (heart failure, coronary artery disease, and/or arrhythmia)
- •Hypersensitivity to study medication
- •treatment with a prohibited medication or anticipation of need for prohibited medication ( section 5.5 )
研究组 & 干预措施
FOLFIRINOX
Experimental
oxaliplatin 85 mg/m2 IV over 2 hours leucovorin 400 mg/m2 over 2 hours irinotecan 150 mg/m2 over 90 min, 5-FU continuous infusion 2400 mg/m2 continuous infusion over 46 hours
干预措施: FOLFIRINOX (Drug)
结局指标
主要结局
Objective response rate
时间窗: up to 2 years
Objective response rate
次要结局
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(every 2 weeks up to 30 weeks.)
- Progression-free survival (PFS)(up to 2years.)
- Overall survival (OS),(up to 5 years.)
- Incidence of febrile neutropenia(After study completion (an average of 2 year))
研究者
Jae-Lyun Lee
professor
Asan Medical Center
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A randomized phase III study of modified FOLFIRINOX (5-FU/LV, irinotecan, and oxaliplatin) versus S-1 alone chemotherapy as second-line chemotherapy for gemcitabine-failed metastatic pancreatic cancerKCT0003534Gyeongsang National University Hospital80
招募中
2 期
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer PatientsPancreatic CancerNCT04084496Sun Yat-sen University80
已完成
2 期
Study of Modified FOLFIRINOX in Advanced Pancreatic CancerMetastatic Pancreatic CancerPancreatic CancerNCT01523457Yale University75
已完成
2 期
Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic CancerPancreatic AdenocarcinomaNCT02749136Asan Medical Center44
终止
2 期
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine CarcinomasGastro-enteropancreatic Neuroendocrine TumorNeuroendocrine Carcinomas of PancreasIslet Cell CarcinomaPancreatic CancerNCT03042780H. Lee Moffitt Cancer Center and Research Institute2